2019年12月6日 ASLAN Pharmaceuticals announces closing of US$15 million Public Offering of American Depositary Shares, including full exercise of underwriter’s option to purchase additional ADSs
2019年11月22日 ASLAN Pharmaceuticals announces publication of preclinical data on ASLAN003 in AML in Haematologica journal
2019年10月22日 ASLAN Pharmaceuticals enrolls first patient in proof-of-concept study for ASLAN004 targeting atopic dermatitis
2019年9月30日 ASLAN Pharmaceuticals and Bukwang Pharmaceutical establish a joint venture, JAGUAHR Therapeutics, to develop novel immuno-oncology therapies
2019年9月19日 ASLAN Pharmaceuticals presents late-breaking data from phase 2 study in China testing varlitinib in second line biliary tract cancer at CSCO
2019年9月10日 Abstract on Aslan Pharmaceuticals’ Varlitinib Accepted for Poster Presentation at ESMO Asia Congress 2019